A Virus That Killed 100% of Bladder Cancers in a Small Trial
ImmVira's oncolytic virus MVR-T3011 just posted a 100% complete response rate in bladder carcinoma in situ at 9 months. The catch? The cohort is tiny. Here's why urologists are watching closely anyway.
The Number That Stopped Urologists in Their Tracks
One hundred percent. That's the complete response rate ImmVira just reported for its oncolytic virus in bladder carcinoma in situ (CIS), a flat, aggressive form of non-muscle-invasive bladder cancer. Every single patient in the optimized-dose group saw their cancer disappear. And it stayed gone at three months, six months, and nine months.
Before you start planning the ticker-tape parade, a critical caveat: the CIS cohort is small. We're talking about a handful of patients in a Phase IIa trial, not a 500-person randomized study. Confidence intervals around 100% in a tiny group are wide enough to drive a truck through. But even with that asterisk, the data presented at ASCO 2026 for MVR-T3011 is turning heads in a disease where patients often face losing their entire bladder.
Why Bladder Cancer Patients Are Desperate for Options
To understand why this matters, you need to understand what happens when the standard treatment fails. The first-line therapy for high-risk bladder CIS is BCG, a tuberculosis vaccine that gets squirted directly into the bladder to fire up the immune system. It works well for many patients. But up to 50% of them see their cancer come back, and of those, roughly two-thirds eventually stop responding altogether.
At that point, the playbook gets grim. The gold-standard recommendation? Radical cystectomy: surgeons remove your entire bladder. It's the most effective option for eliminating the cancer, but it comes with urinary diversion, sexual dysfunction, and a brutal recovery. Think of it like burning down your house to kill a termite infestation. Effective? Sure. Ideal? Not remotely.
Alternatives exist, but none are home runs. Pembrolizumab (Keytruda) is approved for this setting, but it's a systemic IV drug with immune side effects throughout the body. Adstiladrin, an intravesical gene therapy approved in 2022, delivers interferon locally. Anktiva, an IL-15 superagonist combined with BCG, got FDA approval in April 2024. And there's an oncolytic adenovirus called cretostimogene still working through Phase 3. Each offers hope, but .
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
no bladder-sparing therapy has yet matched radical surgery in long-term cancer control
That's the gap ImmVira is trying to fill.
A Virus Designed to Do Three Jobs at Once
MVR-T3011 is what ImmVira calls a "3-in-1" therapy, and the engineering is genuinely clever. It starts with a modified herpes simplex virus (HSV-1) that can replicate inside tumor cells but largely leaves healthy tissue alone. Think of it as a guided missile that only detonates when it reaches the right address.
Once the virus infects a tumor cell, three things happen simultaneously. First, the virus replicates and blows up the cancer cell (oncolysis), spilling tumor debris that alerts the immune system. Second, the dying cell produces an anti-PD-1 antibody locally, essentially a checkpoint inhibitor manufactured right inside the tumor. No systemic infusion needed. Third, the cell churns out IL-12, a protein that supercharges NK cells and T cells while making the tumor environment more hostile to cancer growth.
It's the biological equivalent of a Trojan horse that breaches the wall, calls in reinforcements, and opens the gates from the inside.
For bladder CIS, the virus is delivered intravesically: doctors instill it directly into the bladder through a catheter, putting the drug exactly where it needs to be.
The Data: Electric, but Early
The Phase IIa trial enrolled 46 patients with BCG-unresponsive high-risk bladder cancer, split between a lower dose (2×10⁹ PFU) and the optimized higher dose (1×10¹⁰ PFU). Both groups received induction treatment followed by maintenance dosing over two years.
At the optimized dose, the CIS results were remarkable: 100% complete response rate at 3, 6, and 9 months. The lower dose still performed well but came in at 66.7% complete response at any timepoint. In the papillary tumor subgroup (a different bladder cancer subtype also included in the trial), the optimized dose delivered 90% recurrence-free survival at nine months.
Safety looked clean. Most side effects were mild, Grade 1 or 2. No Grade 4 or 5 events. No treatment-related deaths. No dose-limiting toxicities at the ASCO 2026 data cutoff. For a virus-based therapy injected into the bladder, that's reassuring.
But (and this is a significant "but") the 12-month durability data hasn't matured yet. Follow-up is ongoing, and in oncology, the difference between 9-month and 12-month responses can be the difference between a breakthrough and a footnote. The early CIS cohort at the higher dose had only a handful of patients, and we don't yet know how many were enrolled at that specific dose for CIS.
The Bigger Picture: Can Oncolytic Viruses Finally Break Through?
Oncolytic viruses have been one of biotech's most tantalizing "almost" stories. The concept is decades old: use a virus to selectively infect and destroy cancer cells. Amgen's T-VEC (Imlygic) got FDA approval for melanoma back in 2015, but the field has struggled to replicate that success in other solid tumors.
Bladder cancer, though, might be the perfect proving ground. The organ is essentially a hollow sac, making direct drug delivery straightforward. There's already a precedent for intravesical immunotherapy (BCG has been used this way since the 1970s). And the patient population is desperate; BCG-unresponsive patients face a binary choice between losing their bladder and rolling the dice on therapies with modest track records.
ImmVira clearly sees the opportunity. The company has launched a multi-regional Phase II trial targeting roughly 70 patients across 15 to 20 cancer centers in the U.S. and China, with the first patient dosed in June 2025. That larger dataset will be critical. A 100% response rate in a small group needs to survive contact with a bigger, more diverse patient population before anyone should get too excited.
What Comes Next
ImmVira, a Shenzhen-based biotech with about $90 million in venture funding from investors including OrbiMed, GL Ventures (Hillhouse Capital's VC arm), and Huagai Capital, has ambitions well beyond the bladder. MVR-T3011 is also in trials for head and neck cancer and has been tested intravenously in solid tumors. The company even has a collaboration with Roche combining the virus with the MEK inhibitor cobimetinib.
But bladder cancer is where the story gets told first. If the 70-patient Phase II confirms anything close to these early results, and if durability holds at 12 months and beyond, MVR-T3011 could offer thousands of patients a way to keep their bladders while still beating their cancer.
The 12-month data will be the real test. In oncology, early perfection has a way of humbling you. But for patients facing the prospect of radical surgery, even cautious optimism is worth paying attention to.
Clinical & Regulatory
4 min read
Two Biotech Siblings Just Fought Over the Family Business. Only One Won.
Two gene-editing companies born from the same Harvard lab just fought over who gets to treat a rare liver disease. The arbitration ruling has big implications for how the entire CRISPR ecosystem draws battle lines.
